Field Trip’s (FTRP) Next Generation of Psychedelics
Field Trip Health Ltd (TSE:FTRP, OTCMKTS:FTRPF) is the largest vertically integrated psychedelics company. Psychedelics are the first well-known contextual medicine (the experience a patient has when receiving the drug is almost equally important to the science behind the drug itself). Field Trip realizes this fact and is building the clinical infrastructure to deliver psychedelic therapies while also developing next-generation compounds to bring to market.
As well as operating six modern, technology-enabled clinical hubs for psychedelic therapies (Q4 2021 patient services revenues grew by 66% from the previous quarter), Field Trip also has a phone app appropriately named “Trip”. Trip is the first digital phone app for consciousness expansion.
Field Trip is already prescribing the legal psychedelic ketamine in its clinics but has its sights on developing next-generation compounds that improve existing drugs. Psilocybin, for example, has a long therapy time frame (where trips can last a whole day), resulting in clinical difficulties and extra costs. The second challenge psilocybin has is its well-known characterization and the barriers of owning patent technology around the compound.
To solve these limitations, Field Trip is developing FT-104. FT-104 has the same benefits as psilocybin but has half the “trip” time. Field Trip believes FT-104 will be the preferred molecule for patients and doctors because it will be cheaper and more accessible. FT-104 is also a new chemical entity where IP is robust. Field Trip has already applied for a new composition of matter patents and surrounding IP. The company is looking to receive approval from the FDA in 2026/2027 and will therefore have a longer time to generate ROI.
Watch the full interview to learn how big of a market Field Trip believes psychedelics could become and how Field Trip differentiates itself from all competition.
00:46 – Field Trip Health Business Overview
02:30 – Business differentiator & FT-104 novel drug
06:58 – Clinical development timeline
08:02 – Total Addressable Market (TAM)
09:52 – Integrated model to mitigate “bad trips”
11:58 – How patients sign up
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.